Harrington, K., Kitano, S., Parkes, E., Moreno, I., Alonso-Casal, G., & Gambardella, V. (2025). Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors. Taylor & Francis.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
Harrington, Kevin, Shigehisa Kitano, Eileen Parkes, Irene Moreno, Guzman Alonso-Casal, and Valentina Gambardella. Open-label, Phase Ia Study of STING Agonist BI 1703880 Plus Ezabenlimab for Patients with Advanced Solid Tumors. Taylor & Francis, 2025.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
Harrington, Kevin, et al. Open-label, Phase Ia Study of STING Agonist BI 1703880 Plus Ezabenlimab for Patients with Advanced Solid Tumors. Taylor & Francis, 2025.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.